@article{ref1,
title="Off-label marketing and the First Amendment",
journal="New England journal of medicine",
year="2013",
author="Boumil, Marcia M.",
volume="368",
number="2",
pages="103-105",
abstract="On December 3, 2012, a three-judge panel of a U.S. appeals court took a controversial leap toward what some fear will be license by the courts to invalidate a host of state and federal regulations, including some applicable to health care. In recent years, the Supreme Court has broadened the reach of the First Amendment, defining &quot;protected speech&quot; in such a way as to curtail or eliminate certain familiar governmental restraints. (See table for an overview of cases related to commercial speech and the pharmaceutical industry.) At issue in the December 3 opinion - which is doubtless headed for further appeal . . .<p /> <p>Language: en</p>",
language="en",
issn="0028-4793",
doi="10.1056/NEJMp1214926",
url="http://dx.doi.org/10.1056/NEJMp1214926"
}